Publications by authors named "Adi Diab"

Claim this Profile
L
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.
Merve Hasanov, Simin Kiany, Marie-Andrée Forget, Roland Bassett, Michael A Davies, Adi Diab

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, Alexandre Reuben, Zachary A Cooper, Christine N Spencer, Adi Diab

Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature.
Jane Mattei, Lin Ruitao, Michael A Davies, Michael K Wong, Adi Diab

Melanoma Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, Khalida Wani, Merrick I Ross, Adi Diab

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of microbiome in CAR-T cell therapy.
Reham Abdel-Wahab, Travis D Kerr, Daniel J McGrail, Adi Diab, Salah-Eddine Bentebibel

Int Rev Cell Mol Biol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma.
Sydney A Keatts, Aya F Salem, David M Swanson, Ahsan S Farooqi, Andrew J Bishop, Adi Diab

Clin Transl Radiat Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study.
Maria A Lopez-Olivo, Maria E Suarez-Almazor, Gabrielle F Duhon, McKenna Cherry, Huifang Lu, Adi Diab

JMIR Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.
Chantal Saberian, Denái R Milton, Julie Simon, Rodabe N Amaria, Adi Diab

Neurooncol Pract· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series.
Yuanteng Jeff Li, Pavlos Msaouel, Matthew Campbell, Patrick Hwu, Adi Diab

RMD Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Sang T Kim, Yanshuo Chu, Mercy Misoi, Maria E Suarez-Almazor, Jean H Tayar, Adi Diab

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
Helen Gogas, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz Couselo, Adi Diab

NPJ Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, Alexandra P Foster, Ida John, Adi Diab

Nat Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A Lopez-Olivo, Houssein Safa, Adi Diab

Oncoimmunology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V Long, Paolo A Ascierto

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response.
Vishnupriyadevi Parvathareddy, Umut Selamet, Aditi A Sen, Omar Mamlouk, Juhee Song, Adi Diab

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
Anne R Bass, Noha Abdel-Wahab, Pankti D Reid, Jeffrey A Sparks, Cassandra Calabrese, Adi Diab

Ann Rheum Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
Talal El Zarif, Amin H Nassar, Elio Adib, Bailey G Fitzgerald, Jiaming Huang, Adi Diab

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Adi Diab

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study.
Maria A Lopez-Olivo, Gabrielle F Duhon, Juan I Ruiz, Mehmet Altan, Hussein Tawbi, Adi Diab

Cancers (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, Alexandra P Foster, Ida John, Adi Diab

Nat Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross, Adi Diab

Nature· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.
Yifan Zhou, Yusra B Medik, Bhakti Patel, Daniel B Zamler, Sijie Chen, Adi Diab

J Exp Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
Joel Ho, Jane Mattei, Michael Tetzlaff, Michelle D Williams, Michael A Davies, Adi Diab

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis